Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPARC121
- Development stage
- Preclinical
- Lead developer
- SPARC
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
SPARC121 is a small molecule itaconate derivative currently under development by Sun Pharma Advanced Research Company (SPARC). It is designed to modulate the itaconate pathway, an endogenous metabolic route that plays a critical role in regulating inflammatory and immune responses, particularly within macrophages. By mimicking or enhancing the effects of itaconate, SPARC121 aims to exert potent anti-inflammatory and immunomodulatory activity. The asset is in the early stages of development (discovery/preclinical) for the treatment of autoimmune dermatological conditions, specifically alopecia areata and vitiligo.
Beyond the preview
Go deeper on SPARC121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPARC121.